MALVERN, Pa.--(BUSINESS WIRE)--Promedior announces publication of research in the Journal of Allergy and Clinical Immunology demonstrating pentraxin-2/SAP is a potent inhibitor of asthma and asthma-induced lung fibrosis.
Researchers will also evaluate strategies for children, communities, homes, and schools
MALVERN, Pa.--(BUSINESS WIRE)--Promedior announces initiation of phase 2a clinical study of anti-fibrotic therapeutic, PRM-151, in the prevention of post-surgical scarring in glaucoma patients.
National Institutes of Health supports research to understand how genes affect responses to medicines in leukemia
Metformin, a drug commonly used to treat type 2 diabetes, shows potential in the prevention of tobacco-induced lung tumors, according to early research conducted at the National Cancer Institute (NCI).Results of this study will be published in the September issue of Cancer Prevention Research, a journal of the American Association for Cancer Research. Scott Lippman, M.D., editor-in-chief of ...
MALVERN, Pa.----Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery.
|